Vas Narasimhan, chief executive officer of Swiss pharmaceutical giant Novartis, has joined the board of Anthropic, the San Francisco-based artificial intelligence company, according to an appointment made through the Anthropic Long-Term Benefit Trust. The move marks a significant cross-sector alignment between one of the world’s largest drugmakers and a leading AI safety-focused research organization, underscoring the pharmaceutical industry’s growing recognition that advanced AI systems will reshape drug discovery, development, and patient care in the coming decade.
Narasimhan, who took the helm at Novartis in 2018, has spent his tenure repositioning the company away from traditional blockbuster drug models toward precision medicine and digital health solutions. The Indian-born executive, who previously held senior roles at McKinsey and Company and Emulate Inc., brings deep experience navigating the intersection of healthcare, technology, and large-scale organizational transformation. His appointment to Anthropic’s board comes as pharmaceutical companies worldwide race to integrate generative AI into their research pipelines, clinical trial designs, and drug development workflows.
Anthropic, founded in 2021 by former OpenAI researchers including Dario and Daniela Amodei, has positioned itself as the safety-conscious alternative in the competitive AI space, emphasizing constitutional AI principles and responsible development practices. The company has attracted investment from major institutional players including Google, Salesforce, and others. Narasimhan’s addition to the board reflects Anthropic’s expansion beyond its traditional base of AI researchers and engineers into sectors where its technology could have substantial real-world applications. The appointment also signals confidence from a Fortune 500 pharmaceutical executive in Anthropic’s long-term viability and governance model.
For Novartis, the board position represents a strategic hedge and information channel into cutting-edge AI development. Pharmaceutical companies face immense pressure to accelerate drug discovery timelines while managing soaring research and development costs. Advanced AI models like those being developed by Anthropic could help identify drug candidates more quickly, predict protein structures, design clinical trials with greater precision, and personalize treatment approaches. By placing its CEO on Anthropic’s board, Novartis positions itself to shape how those tools are developed and potentially gain early access to breakthroughs relevant to the drug development pipeline.
The appointment also carries implications for how AI governance intersects with healthcare regulation. Narasimhan, as someone responsible for a company subject to rigorous FDA oversight and global medical device regulations, brings regulatory expertise and real-world accountability perspective to Anthropic’s board discussions. This matters because AI systems used in pharmaceutical development and clinical decision-making will eventually require regulatory scrutiny comparable to the drugs they help discover. Anthropic’s engagement with established pharma leadership suggests the company is thinking beyond research applications toward deployment in regulated industries where safety, transparency, and explainability are non-negotiable.
From an Indian perspective, Narasimhan’s role is noteworthy. The Novartis CEO represents the growing influence of Indian-origin executives in shaping global technology and healthcare strategies. India’s own pharmaceutical sector, dominant in generic drug manufacturing and increasingly active in drug discovery, stands to be affected by AI breakthroughs in the space. Indian biotech companies like Lupin, Dr. Reddy’s, and Cipla, along with contract research organizations such as WuXi AppTec and Syneos Health, will need to integrate advanced AI tools to remain competitive. Narasimhan’s positioning could create precedent for how Indian pharmaceutical leaders engage with frontier AI companies.
Looking ahead, watch for concrete collaborations between Novartis and Anthropic on specific research initiatives. Board appointments often precede deeper commercial partnerships. The pharmaceutical industry’s broader pivot toward AI adoption will depend on how well companies like Novartis can integrate advanced language models into their operations while maintaining regulatory compliance and data privacy standards. Narasimhan’s presence on Anthropic’s board suggests the company is preparing for that future. Additionally, monitor whether other major pharmaceutical companies follow suit with similar appointments, which would indicate the sector is converging on AI as essential infrastructure for 21st-century drug development.
